Study of Intradermal Injections of RCS-01 in Male & Female Subjects

Status Completed

Clinical Trial Summary

The primary purpose of this study is to assess the safety profile of RCS-01 injections as compared to placebo injections. This study will also measure the impact these injections will have on skin markers related to aging through evaluation of gene expression profiles.

30 participants will be selected for this study based on their health status, current/past medications, and ability to adhere to protocol-related requirements. At the first visit and after providing informed consent, participants are evaluated against the study inclusion/exclusion criteria and provide blood samples for screening assessments (including virology). If suitable for study participation, participants will provide a biopsy from the scalp from which RCS-01 will be prepared and will have four treatment evaluation sites identified on their buttocks, two on each side.

Study participants will be randomized to one of two treatment subgroups. Participants in the RCS-01 Subgroup (n=24) will receive injections of RCS-01 or placebo or a 'sham' injection (a needle penetration without injection of liquid). Participants in the the Placebo Subgroup (n= 6) will be randomized to receive only injections of placebo or sham injections.

Baseline evaluations of subjects' overall health and skin condition at treatment sites on their buttocks will be performed before receipt of injections at Day 0. In addition to injections delivered at Day 0, the pre-selected treatment evaluation sites will receive intradermal injections of RCS-01 or placebo (cryomedium) or a sham injection four (4) and eight (8) weeks after Day 0 according to a randomization schedule for a total of three (3) injections per treatment site.

All participants will return to the clinic for at least 9 visits during the 52-week follow-up period to monitor long-term safety. At the 12-week time point, 18 randomly-selected participants from the RCS-01 Subgroup will provide biopsies from all injection sites for analysis of skin markers related to aging. At the 26-week time point, the remaining participants will provide biopsies of all injection sites for histopathological analysis.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02391935
Study type	Interventional
Source	RepliCel Life Sciences, Inc.
Contact
Status	Completed
Phase	Phase 1
Start date	October 10, 2015
Completion date	July 12, 2017

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04606368` - Bausch Health Thermage FXL for Use on Lower Face and Submentum Area	N/A
Completed	`NCT01205061` - Emervel® Deep Lidocaine vs. Juvederm® Ultra Plus in Treatment of Moderate to Severe Facial Wrinkles and Folds	N/A
Completed	`NCT01205048` - Emervel Classic Lidocaine Versus Juvederm® Ultra in Treatment of Moderate to Severe Facial Wrinkles and Folds	N/A
Completed	`NCT01029301` - Evaluation of Safety and Efficacy of Using EndyMed Pro Skin Treatment System for Skin Wrinkle Treatment on Body Areas	N/A
Completed	`NCT04861766` - Safety and Effectiveness of STYLAGE® L for Correction of Moderate and Severe Nasolabial Folds in Chinese Adults	N/A
Completed	`NCT00114673` - A Study to Validate Cosmetic Outcome Scales Used to Rate Uneven Skin Color and Wrinkling	N/A
Completed	`NCT00111254` - The Effects of Microdermabrasion on Skin Remodeling	N/A
Completed	`NCT00945685` - Evaluation of Safety and Efficacy of Using Imagine™ Computerized Radiofrequency System for Skin Tightening	N/A
Completed	`NCT05720000` - Use of Red Light Emitting Diode (LED) and Polydioxanone Thread in Glabellar Wrinkles	N/A
Completed	`NCT01732809` - Fields Of Effects Of Two Commercial Preparations Of Botulinum Toxin Type A At Equal Labeled Unit Doses	Phase 4
Completed	`NCT06451822` - Efficacy and Performance Evaluation of mIntense L+AS 25 mg/ml Hyaluronic Acid for the Correction of Moderate to Deep Wrinkles and Folds	N/A
Completed	`NCT00250952` - Study to Determine If the Volume Used to Dilute BOTOX Cosmetic™ for Injection Affects Its Overall Effect and Duration.	N/A
Completed	`NCT03505684` - Effect of Oral Collagen Tripeptide on Skin Moisture and Wrinkles in Adult Women	N/A
Completed	`NCT02832583` - Autologous Platelet Rich Plasma Combined to Hyaluronic Acid Obtained With Regen-Kit BCT-HA in Aesthetic Medicine	N/A
Completed	`NCT00113100` - Mechanisms of Skin Repair by Topical Estrogen	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Study of Intradermal Injections of RCS-01 in Male and Female Subjects

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms